Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.
